相似文献
1
The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.
Clin Immunol. 2017 Feb;175:10-15. doi: 10.1016/j.clim.2016.11.008. Epub 2016 Nov 23.
2
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.
Drugs. 2016 Jul;76(11):1067-79. doi: 10.1007/s40265-016-0603-2.
3
Evaluation and Optimization of designed Sphingosine-1-Phosphate (S1P) Receptor Subtype 1 Modulators for the Management of Multiple Sclerosis.
Yale J Biol Med. 2017 Mar 29;90(1):15-23. eCollection 2017 Mar.
4
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Cells. 2022 Jun 29;11(13):2058. doi: 10.3390/cells11132058.
5
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Neurology. 2011 Feb 22;76(8 Suppl 3):S3-8. doi: 10.1212/WNL.0b013e31820d5ec1.
6
[Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(2 Pt 2):93-7.
7
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. doi: 10.1212/WNL.0b013e31820db341.
8
FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
Mult Scler. 2012 Mar;18(3):258-63. doi: 10.1177/1352458512438723.
9
Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Arch Pharm Res. 2010 Oct;33(10):1567-74. doi: 10.1007/s12272-010-1008-5. Epub 2010 Oct 30.
10
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
J Neurol Sci. 2013 May 15;328(1-2):9-18. doi: 10.1016/j.jns.2013.02.011. Epub 2013 Mar 19.
引用本文的文献
1
Metabolites as regulators of autoimmune diseases.
Front Immunol. 2025 Aug 21;16:1637436. doi: 10.3389/fimmu.2025.1637436. eCollection 2025.
2
Genomics-informed drug-repurposing strategy identifies two therapeutic targets for preventing liver disease associated with metabolic dysfunction.
Am J Hum Genet. 2025 Aug 7;112(8):1778-1791. doi: 10.1016/j.ajhg.2025.06.014.
3
Cerebrospinal fluid metabolomics in autistic regression reveals dysregulation of sphingolipids and decreased β-hydroxybutyrate.
EBioMedicine. 2025 Apr;114:105664. doi: 10.1016/j.ebiom.2025.105664. Epub 2025 Mar 25.
4
Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.
medRxiv. 2025 Feb 21:2025.02.18.25321035. doi: 10.1101/2025.02.18.25321035.
5
Current understanding of cardiovascular autonomic dysfunction in multiple sclerosis.
Heliyon. 2024 Aug 3;10(15):e35753. doi: 10.1016/j.heliyon.2024.e35753. eCollection 2024 Aug 15.
6
Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia.
Front Immunol. 2024 Jun 17;15:1380975. doi: 10.3389/fimmu.2024.1380975. eCollection 2024.
7
In Vivo Ocular Pharmacokinetics and Toxicity of Siponimod in Albino Rabbits.
Mol Pharm. 2024 Jul 1;21(7):3310-3320. doi: 10.1021/acs.molpharmaceut.4c00063. Epub 2024 Jun 10.
8
Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
Int J Mol Sci. 2024 Feb 20;25(5):2454. doi: 10.3390/ijms25052454.
9
Intestinal Inflammation and Regeneration-Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease.
Int J Mol Sci. 2024 Jan 21;25(2):1311. doi: 10.3390/ijms25021311.
10
A systematic review of immune-based interventions for perinatal neuroprotection: closing the gap between animal studies and human trials.
J Neuroinflammation. 2023 Oct 20;20(1):241. doi: 10.1186/s12974-023-02911-w.
本文引用的文献
1
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.
Lancet Neurol. 2016 Oct;15(11):1148-59. doi: 10.1016/S1474-4422(16)30192-2. Epub 2016 Aug 16.
2
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Lancet Neurol. 2016 Apr;15(4):373-81. doi: 10.1016/S1474-4422(16)00018-1. Epub 2016 Feb 12.
3
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.
J Neuroinflammation. 2016 Feb 8;13:31. doi: 10.1186/s12974-016-0494-x.
4
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis.
CNS Drugs. 2016 Feb;30(2):135-47. doi: 10.1007/s40263-015-0297-0.
5
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus.
Front Immunol. 2015 Oct 28;6:550. doi: 10.3389/fimmu.2015.00550. eCollection 2015.
6
S1P signaling: new therapies and opportunities.
F1000Prime Rep. 2014 Dec 1;6:109. doi: 10.12703/P6-109. eCollection 2014.
7
The diagnosis and classification of polymyositis.
J Autoimmun. 2014 Feb-Mar;48-49:118-21. doi: 10.1016/j.jaut.2014.01.025. Epub 2014 Jan 22.
8
Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.
Pharmaceuticals (Basel). 2012 May 18;5(5):514-28. doi: 10.3390/ph5050514.
9
Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis.
Am J Manag Care. 2013 Feb;19(2 Suppl):S15-20.
10
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
J Neurol Sci. 2013 May 15;328(1-2):9-18. doi: 10.1016/j.jns.2013.02.011. Epub 2013 Mar 19.
Zotero 插件